THE FIRST AND ONLY FDA APPROVED DRUG FOR THE TREATMENT OF AGITATION ASSOCIATED WITH ALZHEIMER'S DEMENTIA: BREXPIPRAZOLE

Year 2024, Volume: 5 Issue: 1, 32 - 33, 28.03.2024

Doğancan Sönmez

Abstract

Alzheimer's dementia is a common neurodegenerative disease that is often associated with memory loss and decline in cognitive function. Agitation that occurs as a symptom of this disease can seriously impact an individual's quality of life and can also be challenging for caregivers. This article will focus on the treatment of agitation associated with Alzheimer's dementia, specifically examining the role of Brexpiprazole, the first and only drug approved by the FDA.

Keywords

Alzheimer, dementia, agitation, brexpiprazole

ALZHEİMER DEMANSIYLA İLİŞKİLİ AJİTASYONUN TEDAVİSİNDE FDA ONAYLI İLK VE TEK İLAÇ: BREXPİPRAZOL

Abstract

Alzheimer demansı, genellikle hafıza kaybı ve bilişsel fonksiyonlarda azalma ile ilişkilendirilen yaygın bir nörodejeneratif hastalıktır. Bu hastalığın bir belirtisi olarak ortaya çıkan ajitasyon, bireyin yaşam kalitesini ciddi şekilde etkileyebilir ve aynı zamanda bakım verenler için de zorlayıcı olabilir. Bu makale, Alzheimer demansıyla ilişkili ajitasyonun tedavisine odaklanarak, özellikle de FDA tarafından onaylanan ilk ve tek ilaç olan Brexpiprazol'ün rolünü inceleyecektir.

Keywords

alzheimer, demans, ajitasyon, brexpiprazol

References

• Referans1. Banerjee S, Smith SC, Lamping DL, et al. Quality of life in dementia: more than just cognition. an analysis of associations with quality of life in dementia. J Neurol Neurosurg Psychiatry. 2006;77:146-8.
• Referans2. Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, et al. Institutionalization risk and costs associated with agitation in Alzheimer's disease. Alzheimers Dement. 2019;5:851-61.
• Referans3. Rockwood K, Sanon Aigbogun M, Stanley J, et al. The symptoms targeted for monitoring in a web-based tracking tool by caregivers of people with dementia and agitation: cross-sectional study. J Med Internet Res. 2019;21:e13360.
• Referans4. Liu KY, Stringer AE, Reeves SJ, et al. The neurochemistry of agitation in Alzheimer's disease: a systematic review. Ageing Res Rev. 2018;43:99-107.
• Referans5. Schein J, Houle CR, Urganus AL, et al. The impact of agitation in dementia on caregivers: a real-world survey. J Alzheimers Dis. 2022;88:663-77.
• Referans6. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:589-604.
• Referans7. Grossberg G, Lee D, Slomkowski M, et al. Efficacy and safety of Brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials. Am J Geriatr Psychiatry. 2023;31:99-100.
• Referans8. Lee D, Slomkowski M, Hefting N, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. JAMA Neurol. 2023;80:1307-16.